Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | FABP1 | P07148 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336243 | 0.87 | TRIM58 (0.48) | TRIM58MAP4K4AKT1AKT2PIK3CA | |
| SCHEMBL3335317 | 0.87 | MAP4K4 (0.48) | MAP4K4DHFRCDK8 | |
| SCHEMBL5131652 | 0.87 | TRIM58 (0.41) | TRIM58AKT1AKT2SCN9ACNR2 | |
| SCHEMBL3336526 | 0.84 | CNR1 (0.46) | TRIM58AKT1AKT2SCN9APIK3CA | |
| SCHEMBL3335859 | 0.82 | TRIM58 (0.47) | TRIM58NR1H4MAP4K4AKT1AKT2 | |
| SCHEMBL3336878 | 0.82 | TRIM58 (0.46) | TRIM58MAP4K4CNR2 | |
| SCHEMBL3337708 | 0.81 | TRIM58 (0.49) | TRIM58MAP4K4DHFRLRRK2PIP5K1C | |
| SCHEMBL3334937 | 0.81 | MAP4K4 (0.46) | MAP4K4DHFRCDK8LRRK2CRBN | |
| SCHEMBL3337208 | 0.81 | CNR2 (0.47) | TRIM58MAP4K4CNR2 | |
| SCHEMBL3334542 | 0.80 | MEN1 (0.45) | TRIM58MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | TRIM58 1431/4885NR1H4 555/4885MAP4K4 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.